Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

FDA concedes delays in response to baby formula shortage

U.S. health regulators say their response to the ongoing infant formula shortage was slowed by delays in processing a whistleblower complaint and test samples from the nation’s largest formula factory

The Independent UK

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

StockNews.com

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

EU health regulator says COVID pandemic not over

An official at the European Union's drugs regulator said on Tuesday the COVID-19 pandemic was not over, contradicting U.S. President Joe Biden, and that a planned vaccination campaign in the region during the cold season was key to fighting it.

Reuters

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (&ld

Benzinga

State, federal red tape hampers opioid treatment

A new Pew analysis found that both state and federal regulations make access to opioid treatment burdensome.

Axios

GAVI financing to allow for immediate funds for next pandemic

Global vaccine alliance GAVI has set up financial instruments that will allow the group to immediately access pledged donor funding if it needs to buy vaccines for future pandemics, Chief Executive Seth Berkley told Reuters.

Reuters

Read news from The Economist, FT, and more,
with one subscription

Biotech firm Oncogeni acquired in £5.5m deal

Roquefort Therapeutics has bought company and also raised capital through share placing to fund pre-clinical drug development programs

Birmingham Post

Biological weapons threat evolving, experts say

WASHINGTON — The threat from biological weapons use by nations or terrorists is entering an era of potentially heightened risk, but the dimensions of the danger are not yet clear, a panel of experts said Friday.

Tribune News Service

Family Dollar recalls Colgate products that were improperly stored

Family Dollar says it is not aware of any complaints from customers nor any reports of illnesses related to the recall.

WEKU

Jury says Sterigenics should pay $363 million to Illinois woman for exposing her to cancer-causing ethylene oxide

Sterigenics, its parent company and a corporate predecessor should pay $363 million in damages for exposing a Willowbrook, Illinois, woman and thousands of others to cancer-causing ethylene oxide pollution, a Cook County jury decided Monday.

Chicago Tribune

The tide turns against superbugs

Humans were losing the war against antibiotic-resistant superbugs. Is that about to change?

Salon

Check Out What Whales Are Doing With BNTX

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Fauci warns strengthening anti-vax movement may lead to ‘tragic and avoidable’ outbreaks among children

According to WHO data, the rates of typical childhood vaccinations have only fallen a point between 2021 and 2020

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Doctors rush to use Supreme Court ruling to escape opioid charges

Dr. Nelson Onaro conceded last summer that he’d written illegal prescriptions, although he said he was thinking only of his patients. From a tiny clinic in Oklahoma, he doled out hundreds of opioid pills and dozens of fentanyl patches with no legitimate medical purpose.

StockNews.com

Should You Buy This Biotech Stock Near Its 52-Week Low?

Recently listed biotech stock Comera Life Sciences is trading near its 52-week low. The stock is down more than 75% year-to-date. Although the $15 million purchase agreement with Arena Business Solutions is expected to help it invest in its product pipeline and formulation platform SQore, will it be wise to…

Reuters

Brazil approves Pfizer vaccine for children as young as six months

Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.

Benzinga

FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

1 Stock You'll Wish You Bought Sooner

Amid the highly uncertain market conditions, investors must look for stocks with ample room for growth and better stability. Biopharmaceutical major Pfizer’s (PFE) products remain in demand irrespective of economic cycles. Given its robust financials, discounted valuation, and high profitability, it could be wise to invest in this defensive stock.…

StockNews.com

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com

1 Stock That’ll Make You Turn Blue in the Face for Owning

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

Axios

America's fentanyl problem a growing threat for teens

America's epidemic of drug overdoses tied to fentanyl is a growing threat for teens, particularly as the pills are increasingly disguised, officials warn.

Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

StockNews.com

2 Reliable Drug Stocks to Buy and Hold for Big-Time Gains

Persistent rate hikes by the Fed and rising odds of a recession have aggravated market turbulence and led investors to seek refuge in defensive sectors such as healthcare. Defensive stocks tend to perform well in declining markets due to the steady demand for their products. Hence, consistent dividend-yielding drug stocks…

The Independent UK

US warns monkeypox could mutate to resist antiviral drug

U.S. health officials are warning doctors against overusing the lone drug available to treat monkeypox

1 … 129 130 131 132

People

Joe Biden

68,071 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.